Table 1 Patient characteristics.

Median age (range)

53 (25–73)

Sex

Female

31

77.5

Male

9

22.5

Performance status (ECOG)

0

8

20

1

30

75

2

2

5

Malignancy type

Breast

19

47.5

Ovary

7

17.5

Pancreas

3

7.5

Lung cancer: non-small cell

2

5

Other*

9

22.5

Prior therapy

Chemotherapy

40

100

Hormone therapy

14

35

Immunotherapy

8

20

Radiotherapy

24

60

PARP inhibitor**

8

20

Prior platinum

32

80

Other systemic therapy

11

27.5

Other therapy

5

12.5

Number of prior lines of therapy

1

4

10

2

4

10

3

11

27.5

≥4

21

52.5

Number of prior chemotherapy regimens–neoadjuvant

1

7

17.5

2

1

2.5

Number of prior chemotherapy regimens–adjuvant

1

14

35

2

1

2.5

Number of prior chemotherapy regimens–advanced/metastatic disease

1

9

22.5

2

11

27.5

3

9

22.5

≥4

8

20

Mutation Status (known at study enrollment)

Germline BRCA1

6

15

Germline BRCA2***

13

33

Somatic BRCA1 or 2

3

8

PALB2 ***

1

2.5